Abstract: Improved methods for the simultaneous production of dihydroxybenzene and dicarbinol from diisopropylbenzene are provided. These methods provide for continuous and simultaneous production of diisopropylbenzene dihydroperoxide (DHP) and diisopropylbenzene hydroxyhydroperoxide (HHP) using Karr Column extractors operated in series. A very high purity DHP-containing solution, the precursor to the dihydroxybenzene, can be produced according to the reported methods. A safe and efficient method for producing dicarbinol from HHP is also disclosed.

Abstract: A pressurized container with an aerosol pharmaceutical formulation, and a process for making the formulation, are provided. The formulation comprises a pharmaceutical agent, a phenol, glycerin or polyglycerin, and an additional ingredient such as an alkali metal alkyl sulfate, polidocanol alkyl ether or the like. The formulation is placed in the pressurized container, which is then charged with a propellant. A method of treating a medical condition, by spraying the formulation into the mouth or lungs, is also provided.

Abstract: Methods for transferring one or more proteins to a cell are disclosed. The protein or proteins to be transferred are in the form of a fusion protein, and contain at least one domain encoding for a protein or peptide having trans signaling and/or adhesion function. The fusion protein is transferred to a cell by binding to a lipidated protein, which has been incorporated into the cell membrane. Methods for using cells which have undergone protein transfer according to the present methods are also disclosed. This includes use in a cancer vaccine, use for treatment of cancer or autoimmune disease, and use in determining costimulator threshold levels.

Abstract: A mixed micellar aerosol pharmaceutical formulation is provided. The formulation comprises a pharmaceutical agent, an alkali metal alkyl sulphate, at least three micelle-forming compounds, a phenol and a propellant. The propellant provides enchanced absorption of the pharmaceutical agent in the buccal region. A process of making and a method of administering the composition are also included.

Abstract: Novel diol blends are disclosed. The blends are comprised of an aromatic diol portion derived from dihydric phenol and an aliphatic diol portion in a ratio of aromatic to aliphatic of 5:95 to 95:5. The aromatic portion is the reaction product of a dihydric phenol and one or more alkylene carbonates using a stoichiometric excess of carbonate. Methods for preparing these diol blends are also disclosed, as are methods for using these compounds in the preparation of cast elastomers. Cast elastomers prepared from these blends are also disclosed; the elastomers have physical and mechanical properties that make them appropriate for use in many demanding applications.

Abstract: An aerosol pharmaceutical formulation for pulmonary and nasal delivery is provided. The formulation comprises a pharmaceutical agent, water, a phenol and a propellant. Optionally, an excipient such as glycerin or polyglycerin, lysine or polylysine, or other salts, flavoring or coloring agents, protease inhibitors or stabilizers can be added. A method of administering the formulation with a metered dose dispenser, and a dispenser containing the formulation are also provided.

Abstract: A mixed liposome pharmaceutical formulation with multilamellar vesicles is provided. The formulation comprises a pharmaceutical agent, water, an alkali metal alkyl sulfate, at least one membrane mimetic amphiphile, and at least one phospholipid. When aerosol delivery is intended, the formulation also comprises a propellant and a phenol. A metered dose dispenser containing the formulation, as well as a method of administering the formulation, are also provided.

Abstract: Sulfatase inhibitor compounds useful in the treatment of estrogen dependent illnesses are disclosed. These compounds generally comprise a steroid nucleus substituted at the C17 position. Methods for synthesizing these compounds and using them in the therapeutic and/or prophylactic treatment of a patient are also disclosed.

Abstract: A mixed liposome pharmaceutical composition with multilamellar vesicles is provided. The vesicles are comprised of a pharmaceutical agent, membrane-mimetic amphiphiles and various phospholipids. A method of making the composition using high speed mixing of the amphiphiles and phospholipids is also provided.

Abstract: An article intended to be contacted with a baby's mouth when sucking, or in form of a breast hood, the article comprises a wall at least part of a surface of it including a material which is able to be stretched at least twice in dimension under a tension corresponding to a suction force of at least 130 mm Hg. This article may be realized in the form of a combination of a baby's bottle and an assigned nipple. The baby's bottle may further comprise an outer surface to be gripped which is made at least in part from a second material having a predetermined elasticity and bulging out from the rigid material of the bottle.

Abstract: A method and apparatus is provided for producing a porous metal. The method broadly includes the steps of first, providing a molten metal and second, introducing a gas into said molten metal. The method then includes spray casting the molten metal containing the gas onto a surface thereby producing the porous metal. The method further provides for controlling the amount and size of the porosity contained within the porous metal by controlling the parameters at which the gas is introduced into the molten metal, as well as, controlling the parameters surrounding the spray casting of the molten metal. Additionally, the method also provides for producing a porous metal having either an isolated or interconnected pore structure. The present invention also provides for a porous metal product, as well as a porous aluminum alloy product, made by the described method. The apparatus includes a means for containing the molten metal wherein the containing means has a discharge end.

Abstract: A mixed micellar pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal C8 to C22 alkyl sulphate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compounds. The absorption enhancing compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixtures thereof. The amount of each absorption enhancing compound is present in a concentration of from 1 to 10 wt./wt. % of the total formulation, and the total concentration of absorption enhancing compounds are less than 50 wt./wt. % of the formulation.

Abstract: A mixed micellar pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an lkali metal C8 to C22 alkyl sulphate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compounds. The absorption enhancing compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixtures thereof. The amount of each absorption enhancing compound is present in a concentration of from 1 to 10 wt./wt. % of the total formulation, and the total concentration of absorption enhancing compounds are less than 50 wt./wt. % of the formulation.

Abstract: Shot for shotgun cartridges is made form finely divided particles of dense metal such as a mixture of tungsten and molybdenum, bound by a matrix which may comprise ethylene propylene copolymer, or a blend of a terpolymer of ethylene, acrylic ester and maleic anhydride or an ionomer either alone or blended with such terpolymer or with a stock polymer material or a blend of polymers. Shot may be produced from such material by forming it into a strip, web or strand which is passed between aligned rollers with cooperating hemispherical indentations and thereafter punching the resulting shot from the resulting thin web.

Abstract: A liposome pharmaceutical composition is provided. The liposomes are comprised of a medicinally active agent, at least three phospholipids and at least two biodegradable polymers. The liposomes can be used for delivery of various cosmetics and drugs, and can be administered orally, topically or by injection.

Abstract: A mixed liposome pharmaceutical formulation with multilamellar vesicles, comprises a proteinic pharmaceutical agent, water, an alkali metal lauryl sulphate in a concentration of from 1 to 10 wt./wt. %, at least one membrane-mimetic amphiphile and at least one phospholipid.

Abstract: A substrate system for receiving a deposit of sprayed metal droplets including a movable outer substrate on which the sprayed metal droplets are deposited. The substrate system also includes an inner substrate disposed adjacent the outer substrate where the sprayed metal droplets are deposited on the outer substrate. The inner substrate includes zones of differing thermal conductivity to resist substrate layer porosity and to resist formation of large grains and coarse constituent particles in a bulk layer of the metal droplets which have accumulated on the outer substrate. A spray forming apparatus and associated method of spray forming a molten metal to form a metal product using the substrate system of the invention is also provided.